Merck seeks FDA EUA for COVID-19 drug molnupiravir |
Clinical News
eMediNexus Coverage from: 
Merck seeks FDA EUA for COVID-19 drug molnupiravir

0 Read Comments                

Merck has sought emergency use authorization from the US Food and Drug Administration for its experimental antiviral COVID-19 drug, molnupiravir, stated the company.If authorized, the drug would become the first oral antiviral approved for the treatment of COVID-19. The drug comes in capsule form.Merck and Ridgeback announced interim data from the phase III clinical trial showing that molnupiravir could decrease the risk of hospitalization or death by about 50%. Nearly 7% of patients who receive...
To read the complete article ,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now